Barrenetxea Lekue, Cristina http://orcid.org/0000-0002-9777-8788
Grasso Cicala, Silvina
Leppä, Sirpa
Stauffer Larsen, Thomas
Herráez Rodríguez, Susana
Alonso Caballero, Clara
Jørgensen, Judit M.
Toldbod, Helle
Leal Martínez, Irene
D’Amore, Francesco
Funding for this research was provided by:
SERVIER SPAIN FOR THE MEDICAL WRITING ASSISTANCE (NOT APPLICABLE)
Article History
Received: 20 March 2019
Accepted: 20 June 2019
First Online: 17 July 2019
Compliance with ethical standards
:
: Cristina Barrenetxea Leuke has been a speaker for Janssen, Roche, and Servier and has participated on a board for Celgene and Janssen. Sirpa Leppä has participated on a board for Celgene, Novartis, and MSD, and received research funding from Celgene, Roche, Takeda, Bayer and Janssen. Susana Herráez Rodríguez has participated on a board for Celgene and Janssen. Clara Alonso Caballero and Irene Leal Martínez have no conflicts of interest to declare. Silvina Grasso Cicala is an employee of Servier. Judit Meszaros Jørgensen has participated on a board of Gilead. Helle Toldbod has no conflicts of interest to declare. Francesco D’Amore has received research funding from Takeda, Servier, and Sanofi and has participated on a board for Takeda, Servier, Nordic Nanovector, and Kyowa Kirin. Thomas Stauffer Larsen has participated on a board for Takeda and Roche.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: This article does not contain any studies with human participants performed by any of the authors.